The fragile x-associated tremor and ataxia syndrome (FXTAS);A síndrome de tremor e ataxia associada ao X frágil (FXTAS)

Arquivos de Neuro-Psiquiatria

Volumn 68, Issue 5, 2010, Pages 791-798

  Capelli, Leonardo Pires ^a   Gonçalves, Márcia Rúbia Rodrigues ^a   Leite, Claudia C ^a   Barbosa, Egberto R ^a   Nitrini, Ricardo ^a   Vianna Morgante, Angela M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CGG repeats; Essential tremor; FMR1 gene; Fragile X syndrome; Fragile X associated tremor ataxia syndrome; FXTAS; Gait ataxia; Movement disorders

Indexed keywords

AMANTADINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIDOPA PLUS LEVODOPA; CITALOPRAM; DONEPEZIL; DULOXETINE; ESCITALOPRAM; GABAPENTIN; GALANTAMINE; MEMANTINE; MIRTAZAPINE; MUSCARINIC M1 RECEPTOR ANTAGONIST; PRAMIPEXOLE; PREGABALIN; PRIMIDONE; PYRIDOSTIGMINE; RIVASTIGMINE; SELEGILINE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; ATAXIA; AUTONOMIC DYSFUNCTION; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC PROCEDURE; FRAGILE X SYNDROME; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; MENTAL DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARKINSONISM; PERIPHERAL NEUROPATHY; PHYSICAL THERAPY EDUCATION; TREMOR;

EID: 78649524958     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2010000500023     Document Type: Article

References (73)

1. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, Parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001; 57:127-130
2. Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet 2004;74:805-816.
3. Miller G. Biomedical research. Fragile X's unwelcome relative. Science 2006;312:518-521.
4. Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 2007;6:45-55.
5. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation trem or/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003;72:869-878.
6. Amiri K, Hagerman RJ, Hagerman PJ. Fragile X-associated tremor/ataxia syndrome: an aging face of the fragile X gene. Arch Neurol 2008;65:19-25.
7. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, et al. Fragile X permutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study-preliminary data. Am J Med Genet 1999;83:322-325.
8. Costa SS, Fonseca AM, Bagnoli VR, Vianna-Morgante AM. The FMR1 premutation as a cause of premature ovarian failure in Brazilian women. Genet Mol Biol 2006;29:423-428.
9. Capelli LP, Goncalves MR, Kok F, et al. Fragile X-associated tremor/ataxia syndrome: intrafamilial variability and the size of the FMR1 premutation CGG repeat. Mov Disord 2007;22:866-870.
10. Jacquemont S, Farzin F, Hall D, et al. Aging in individuals with the FMR1 mutation. Am J Ment Retard 2004;109:154-164.
11. Rogers C, Partington MW, Turner GM. Tremor, ataxia and dementia in older men may indicate a carrier of the fragile X syndrome. Clin Genet 2003; 64:54-56.
12. Bacalman S, Farzin F, Bourgeois JA, et al. Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J Clin Psychiatry 2006;67:87-94.
13. Bourgeois JA, Cogswell JB, Hessl D, et al. Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. Gen Hosp Psychiatry 2007;29:349-356.
14. Grigsby J, Brega AG, Engle K, et al. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychology 2008;22:48-60.
15. Seritan AL, Nguyen DV, Farias ST, et al. Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease. Am J Med Genet B 2008;147:1138-1144.
16. Hall DA, Howard K, Hagerman R, Leehey MA. Parkinsonism in 16. FMR1 premutation carriers may be indistinguishable from Parkinson disease. Parkinsonism Relat Disord 2009;15:156-159.
17. Hagerman RJ, Coffey SM, Maselli R, et al. Neuropathy as a presenting feature in fragile X-associated tremor/ataxia syndrome. Am J Med Genet A 2007;143:2256-2260.
18. Grigsby J, Brega AG, Jacquemont S, et al. Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). J Neurol Sci 2006;248:227-233.
19. Leehey MA, Berry-Kravis E, Min SJ, et al. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord 2007;22:203-206.
20. Hall DA, Berry-Kravis E, Jacquemont S, et al. Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS). Neurology 2005;65:299-301.
21. Brunberg JA, Jacquemont S, Hagerman RJ, et al. Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. Am J Neuroradiol 2002; 23:1757-1766.
22. Loesch DZ, Litewka L, Brotchie P, Huggins RM, Tassone F, Cook M. Magnetic resonance imaging study in older fragile X premutation male carriers. Ann Neurol 2005;58:326-330.
23. Greco CM, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006;129:243-255.
24. Greco CM, Hagerman RJ, Tassone F, et al. Neuronal intranuclear inclusions 24. in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002;125:1760-1771.
25. Gokden M, Al-Hinti JT, Harik SI. Peripheral nervous system pathology in fragile X tremor/ataxia syndrome (FXTAS). Neuropathology 2009;29: 280-284.
26. Coffey SM, Cook K, Tartaglia N, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A 2008;146:1009-1016.
27. Hagerman RJ, Hall DA, Coffey S, et al. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging 2008;3:251-262.
28. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000;66:6-15.
29. Mankodi A, Thornton CA. Myotonic syndromes. Curr Opin Neurol 2002;15: 545-552.
30. Primerano B, Tassone F, Hagerman RJ, Hagerman P, Amaldi F, Bagni C. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA 2002;8:1482-1488.
31. Tassone F, Iwahashi C, Hagerman PJ. FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol 2004;1:103-105.
32. Garcia-Arocena D, Iwahashi CK, Won N, et al. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet 2005;14:3661-3671.
33. Iwahashi CK, Yasui DH, An HJ, et al. Protein composition of the intranuclear inclusions of FXTAS. Brain 2006;129:256-271.
34. Jin P, Duan R, Qurashi A, et al. Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegenerationin a Drosophila model of fragile X tremor/ataxia syndrome. Neuron 2007;55:556-564.
35. Sofola OA, Jin P, Qin Y, et al. RNA-binding proteins hnRNP A2/B1 and CUG BP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 2007;55:565-571.
36. Handa V, Goldwater D, Stiles D, et al. Long CGG-repeat tracts are toxic to human cells: implications for carriers of Fragile X premutation alleles. FEBS Lett 2005;579:2702-2708.
37. Oostra BA, Willemsen R. A fragile balance: FMR1 expression levels. Hum Mol Genet 2003;12:249-257.
38. Willemsen R, Mientjes E, Oostra BA. FXTAS: a progressive neurologic syndrome associated with Fragile X premutation. Curr Neurol Neurosci Rep 2005;5:405-410.
39. Hagerman RJ. Lessons from fragile X regarding neurobiology, autism, and neurodegeneration. J Dev Behav Pediatr 2006;27:63-74.
40. Willemsen R, Hoogeveen-Westerveld M, Reis S, et al. The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet 2003;12:949-959.
41. Van Dam D, Errijgers V, Kooy RF, et al. Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). Behav Brain Res 2005;162:233-239.
42. Jin P, Zarnescu DC, Zhang F, et al. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron 2003;39:739-747.
43. Shan G, Xu S, Jin P. FXTAS: a bad RNA and a hope for a cure. Expert Opin Biol Ther 2008;8:249-253.
44. Kamm C, Gasser T. The variable phenotype of FXTAS: a common cause of "idiopathic" disorders. Neurology 2005;65:190-191.
45. Storey E, Billimoria P. Increased T2 signal in the middle cerebellar peduncles on MRI is not specific for fragile X premutation syndrome. J Clin Neurosci 2005;12:42-43.
46. Mothersead PK, Conrad K, Hagerman RJ, Greco CM, Hessl D, Tassone F. GRAND ROUNDS: an atypical progressive dementia in a male carrier of the fragile X premutation: an example of fragile X-associated tremor/ataxia syndrome. Appl Neuropsychol 2005;12:169-178.
47. Hagerman PJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome (FXTAS). Ment Retard Dev Disabil Res Rev 2004;10:25-30.
48. Van Esch H. The Fragile X premutation: new insights and clinical consequences. Eur J Med Genet 2006;49:1-8.
49. Cohen S, Masyn K, Adams J, et al. Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome. Neurology 2006;67: 1426-1431.
50. Loesch DZ, Litewka L, Churchyard A, Gould E, Tassone F, Cook M. Tremor/ataxia syndrome and fragile X premutation: diagnostic caveats. J Clin Neurosci 2007;14:245-248.
51. Grigsby J, Leehey MA, Jacquemont S, et al. Cognitive impairment in a 65 year-old male with the fragile X-associated tremor-ataxia syndrome (FXTAS). Cogn Behav Neurol 2006;19:165-171.
52. Gonçalves MR, Capelli LP, Nitrini R, et al. Atypical clinical course of FX TAS: rapidly progressive dementia as the major symptom. Neurology 2007;68:1864-1866.
53. Hagerman PJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome an older face of the fragile X gene. Nat Clin Pract Neurol 2007;3:107-112.
54. Cornish KM, Li L, Kogan CS, et al. Age-dependent cognitive changes in carriers of the fragile X syndrome. Cortex 2008;44:628-636.
55. Loesch DZ, Cook M, Litewka L, et al. A low symptomatic form of neurodegeneration in younger carriers of the FMR1 premutation, manifesting typical radiological changes. J Med Genet 2008;45:179-181.
56. Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004;291:460-469.
57. Berry-Kravis E, Abrams L, Coffey SM, et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord 2007;22:2018-2030.
58. Jacquemont S, Orrico A, Galli L, et al. Spastic paraparesis, cerebellar ataxia, and intention tremor: a severe variant of FXTAS? J Med Genet 2005;42:14.
59. Jacquemont S, Leehey MA, Hagerman RJ, Beckett LA, Hagerman PJ. Size bias of fragile X premutation alleles in late-onset movement disorders. J Med Genet 2006;43:804-809.
60. Baba Y, Uitti RJ. Fragile X-associated tremor/ataxia syndrome and move ments disorders. Curr Opin Neurol 2005;18:393-398.
61. Hall DA, Hagerman RJ, Hagerman PJ, Jacquemont S, Leehey MA. Prevalence of FMR1 repeat expansions in movement disorders. A systematic review. Neuroepidemiology 2006;26:151-155.
62. Berry-Kravis E, Lewin F, Wuu J, et al. Tremor and ataxia in fragile X premutation carriers: blinded videotape study. Ann Neurol 2003;53:616-623.
63. Loesch DZ, Churchyard A, Brotchie P, Marot M, Tassone F. Evidence for, and a spectrum of, neurological involvement in carriers of the fragile X pre-mutation: FXTAS and beyond. Clin Genet 2005;67:412-417.
64. Grigsby J, Brega AG, Leehey MA, et al. Impairment of executive cognitive functioning in males with fragile X-associated tremor/ataxia syndrome. Mov Disord 2007;22:645-650.
65. Tassone F, Adams J, Berry-Kravis EM, et al. CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet B Neuropsychiatr Genet 2007;144:566-569.
66. Leehey MA, Berry-Kravis E, Goetz CG, et al. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology 2008;70: 1397-1402.
67. Dombrowski C, Levesque S, Morel ML, Rouillard P, Morgan K, Rousseau F. Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet 2002;11:371-378.
68. Hall DA, Berry-Kravis E, Hagerman RJ, Hagerman PJ, Rice CD, Leehey MA. Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. Mov Disord 2006;21:1741-1744.
69. McConkie-Rosell A, Finucane B, Cronister A, Abrams L, Bennett RL, Pettersen BJ. Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 2005; 14:249-270.
70. Reis AH, Ferreira AC, Gomes KB, et al. Frequency of FMR1 premutation in individuals with ataxia and/or tremor and/or Parkinsonism. Genet Mol Res 2008;7:74-84.
71. Nitrini R, Gonçalves MRR, Capelli LP et al. Dementia in fragile X-associated tremor/ataxia syndrome. Dement Neuropsychol 2010;4:79-83.
72. McConkie-Rosell A, Abrams L, Finucane B, et al. Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders. J Genet Couns 2007;16:593-606.
73. Elaine B, Spector EB, Kronquist K. Technical standards and guidelines for fragile X testing: a revision to the disease-specific supplements to the standards and guidelines for clinical genetics laboratories of the American College of Medical Genetics. Available at www.acmg.net/Pages/ACMG_Activities/stds-2002/fx.htm. Accessed (04/01/2010).